"Clinical activity of folinic acid in patients with chronic fatigue syndrome"
In some embodiments, a formulation described herein, further comprises a gelling agent (e.g., poloxamer 407) and provides release of the therapeutic agent over a period of from about 1 day to about 5 days
The final column reflects other potential applications already popular among peptide users
Nutritional inadequacies in commercial vegan foods for dogs and cats
Proposed use: Ulcerative colitis Proposed forms: Oral capsules, nasal spray, injections, transdermal cream, rectal suppository Proposed use: Wound healing Proposed forms: Subcutaneous or intramuscular injection Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests Proposed use: Wound healing and inflammatory condition Proposed forms: Cream and gel Proposed use: Obesity and osteoporosis Proposed forms: Subcutaneous injection Proposed use: Cerebral ischemia (shortage of blood flow and oxygen to the brain), migraine and trigeminal neuralgia (chronic pain condition in the face) Proposed form: Intranasal spray, subcutaneous injection Click Here To Sign Up For Our Health Newsletter Proposed use: Opioid withdrawal, chronic insomnia, narcolepsy Proposed form: Subcutaneous injection Proposed use: Insomnia Proposed form: Subcutaneous injection Performance medicine and peptide expert Dr
